On March 6th, 2017, Marapharm granted a total of 1,000,000 stock options to company directors, consultants, and employees, with an exercise price of $1.49. 300,000 of these will expire on September 6th, 2017 and 700,000 will expire on June 3rd, 2018. An additional 800,000 stock options were issued with an exercise price of $2.50. These will expire on September 6th, 2017.
Marapharm also granted a total of 3,300,000 stock options on June 28, 2017 to company directors, consultants, and employees, with an exercise price of $1.02 which will expire on June 28th, 2019.
Marapharm has appointed a new auditor and has filed the March 31, 2017 annual audited financial statements and Management’s Discussion and Analysis on July 31, 2017.
Marapharm has issued 300,000 shares from treasury in payment of legal and consulting services incurred with a US firm over the past 18 months.
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company on the Canadian Stock Exchange (CSE: MDM, OTCQB: MRPHF) primarily investing in the medical and recreational cannabis space, with corporate operations based in British Columbia, Canada. Since 2016 they have rapidly expanded their footprint to include production locations in the key North American states of Washington, Nevada, and California. They actively seek expansion opportunities worldwide.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Neither the CSE, the FSE, nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE, nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.